Molecular Characterization of Putative Chordoma Cell Lines

Overview

Journal Sarcoma

Publisher Wiley

Date 2011 Jan 22

PMID 21253487

Citations 37

Authors

Silke Bruderlein

Joshua B Sommer

Paul S Meltzer

Sufeng Li

Takuya Osada

David Ng

Peter Moller

David A Alcorta

Michael J Kelley

Affiliations

Soon will be listed here.

Abstract

Immortal tumor cell lines are an important model system for cancer research, however, misidentification and cross-contamination of cell lines are a common problem. Seven chordoma cell lines are reported in the literature, but none has been characterized in detail. We analyzed gene expression patterns and genomic copy number variations in five putative chordoma cell lines (U-CH1, CCL3, CCL4, GB60, and CM319). We also created a new chordoma cell line, U-CH2, and provided genotypes for cell lines for identity confirmation. Our analyses revealed that CCL3, CCL4, and GB60 are not chordoma cell lines, and that CM319 is a cancer cell line possibly derived from chordoma, but lacking expression of key chordoma biomarkers. U-CH1 and U-CH2 both have gene expression profiles, copy number aberrations, and morphology consistent with chordoma tumors. These cell lines also harbor genetic changes, such as loss of p16, MTAP, or PTEN, that make them potentially useful models for studying mechanisms of chordoma pathogenesis and for evaluating targeted therapies.

Citing Articles

Chordoma cells possess bone-dissolving activity at the bone invasion front.

Kawaai K, Oishi Y, Kuroda Y, Tamura R, Toda M, Matsuo K Cell Oncol (Dordr). 2024; 47(5):1663-1677.

PMID: 38652222 PMC: 11466907. DOI: 10.1007/s13402-024-00946-6.

Impact of silencing eEF2K expression on the malignant properties of chordoma.

Aydemir E, Tuysuz E, Bayrak O, Tecimel D, Hizli-Deniz A, Sahin F Mol Biol Rep. 2023; 50(4):3011-3022.

PMID: 36652154 DOI: 10.1007/s11033-023-08257-z.

efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts.

Passeri T, Dahmani A, Masliah-Planchon J, El Botty R, Courtois L, Vacher S Front Oncol. 2022; 12:960720.

PMID: 36505864 PMC: 9732546. DOI: 10.3389/fonc.2022.960720.

Optimizing CRISPR/Cas9 Editing of Repetitive Single Nucleotide Variants.

Usher I, Ligammari L, Ahrabi S, Hepburn E, Connolly C, Bond G Front Genome Ed. 2022; 4:932434.

PMID: 35865001 PMC: 9294353. DOI: 10.3389/fgeed.2022.932434.

Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.

Hoke A, Padget M, Fabian K, Nandal A, Gallia G, Bilusic M Cancer Res Commun. 2022; 1(3):127-139.

PMID: 35765577 PMC: 9236084. DOI: 10.1158/2767-9764.crc-21-0020.

References

Henderson S, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S . A molecular map of mesenchymal tumors. Genome Biol. 2005; 6(9):R76. PMC: 1242211. DOI: 10.1186/gb-2005-6-9-r76. View

Kristiansen G, Sammar M, Altevogt P . Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004; 35(3):255-62. DOI: 10.1023/b:hijo.0000032357.16261.c5. View

MacLEOD R, Dirks W, Matsuo Y, Kaufmann M, MILCH H, Drexler H . Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer. 1999; 83(4):555-63. DOI: 10.1002/(sici)1097-0215(19991112)83:4<555::aid-ijc19>3.0.co;2-2. View

Liu M, Lin S, Liu H, Candal F, Vafai A . Identification and authentication of animal cell culture by polymerase chain reaction amplification and DNA sequencing. In Vitro Cell Dev Biol Anim. 2004; 39(10):424-7. DOI: 10.1290/1543-706X(2003)039<0424:IAAOAC>2.0.CO;2. View

OHara B, Paetau A, Miettinen M . Keratin subsets and monoclonal antibody HBME-1 in chordoma: immunohistochemical differential diagnosis between tumors simulating chordoma. Hum Pathol. 1998; 29(2):119-26. DOI: 10.1016/s0046-8177(98)90220-9. View

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

Vujovic S, Henderson S, Presneau N, Odell E, Jacques T, Tirabosco R . Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006; 209(2):157-65. DOI: 10.1002/path.1969. View

Drexler H, Dirks W, Matsuo Y, MacLeod R . False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia. 2003; 17(2):416-26. DOI: 10.1038/sj.leu.2402799. View

Sanuki-Fujimoto N, Ishikura S, Hayakawa K, Kubota K, Nishiwaki Y, Tamura T . Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202. Radiat Oncol. 2009; 4:16. PMC: 2698865. DOI: 10.1186/1748-717X-4-16. View

10.

Sommer J, Itani D, Homlar K, Keedy V, Halpern J, Holt G . Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J Pathol. 2010; 220(5):608-17. DOI: 10.1002/path.2679. View

11.

Boonstra J, van Marion R, Beer D, Lin L, Chaves P, Ribeiro C . Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 2010; 102(4):271-4. PMC: 2902814. DOI: 10.1093/jnci/djp499. View

12.

Kispert A, Koschorz B, Herrmann B . The T protein encoded by Brachyury is a tissue-specific transcription factor. EMBO J. 1995; 14(19):4763-72. PMC: 394574. DOI: 10.1002/j.1460-2075.1995.tb00158.x. View

13.

Markovic O, Markovic N . Cell cross-contamination in cell cultures: the silent and neglected danger. In Vitro Cell Dev Biol Anim. 1998; 34(1):1-8. DOI: 10.1007/s11626-998-0040-y. View

14.

Oakley G, Fuhrer K, Seethala R . Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol. 2008; 21(12):1461-9. PMC: 4233461. DOI: 10.1038/modpathol.2008.144. View

15.

Yang C, Schwab J, Schoenfeld A, Hornicek F, Wood K, Nielsen G . A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther. 2009; 8(9):2597-605. DOI: 10.1158/1535-7163.MCT-09-0504. View

16.

Presneau N, Shalaby A, Idowu B, Gikas P, Cannon S, Gout I . Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer. 2009; 100(9):1406-14. PMC: 2694420. DOI: 10.1038/sj.bjc.6605019. View

17.

Zhang D, Ma B, Fan Q, Chang H, Wen Y . [Establishment and characteristics of a human chordoma cell line]. Zhonghua Zhong Liu Za Zhi. 2003; 25(3):234-7. View

18.

Voskoglou-Nomikos T, Pater J, Seymour L . Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003; 9(11):4227-39. View

19.

Casali P, Stacchiotti S, Sangalli C, Olmi P, Gronchi A . Chordoma. Curr Opin Oncol. 2007; 19(4):367-70. DOI: 10.1097/CCO.0b013e3281214448. View

20.

Rhodes D, Barrette T, Rubin M, Ghosh D, Chinnaiyan A . Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002; 62(15):4427-33. View